Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine
Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine
The Vulvar Vestibulitis Clinical Trial (VVCT) a randomized, placebo-controlled, double
 blinded clinical trial. We will study the clinical efficacy of four medical treatments for
 vulvar vestibulitis: topical lidocaine, oral desipramine, combined lidocaine and desipramine,
 and placebo cream and capsules. Desipramine is a tricyclic antidepressant commonly used by
 clinicians for treatment of several chronic pain conditions that demonstrates an optimal side
 effect profile compared to other tricyclic antidepressants. Topical lidocaine has also been
 found to be beneficial for vulvar vestibulitis treatment in small studies. It is hypothesized
 that the combined use of oral desipramine and topical lidocaine will be more therapeutically
 effective than either one by itself and better than placebo.
The Vulvar Vestibulitis Clinical Trial (VVCT) is a randomized, placebo-controlled,
 double-blinded clinical trial to study the clinical efficacy of four medical treatments for
 vulvar vestibulitis: 1) topical lidocaine, 2) oral desipramine, 3) combined lidocaine and
 desipramine, and 4) placebo cream and capsules. The duration of study drug will last 12 weeks
 with post-intervention follow-up at 6 and 12 months. We plan to enroll 128 subjects from the
 university-based clinical program at the University of Rochester (UR).Primary outcome
 variable will compare the reported pain of the "Tampon Test" (mean of Weeks -2, -1, and 0),
 prior to randomization to the reported pain of "Tampon Test" (mean of Weeks 10, 11, and 12).
 The dependent (primary outcome) variable will be defined as the percent change of mean
 "Tampon test" pain of Weeks (10, 11, and 12) from Weeks (-2, -1 and 0). The primary analysis
 of this 2X2 factorial design will involve fitting an Analysis of Covariance (ANCOVA)
 regression model to the percent change of mean "Tampon test" pain with the two treatment
 variables as the predictors while adjusting for the covariate age. We will test if the
 interaction between the two treatments in the ANCOVA model is significant at the .05 level.
 If the interaction effect is not significant, it will be dropped from the model and the
 conclusion will be drawn from the model with main effects only. If significant, the model
 with interactions will be adopted. SAS PROC GLM will be used in the analysis.

 In the case of non-significant interaction, the primary analysis will be based on the ANCOVA
 model with main effects of treatments and adjusting for age. Since there are two treatments
 under investigation, the primary analysis will use the Bonferroni correction, i.e. will set
 alpha level of 0.025 (two-sided) to determine statistical significance. The significance of
 the main effect of each treatment will be assessed by t-tests in the ANCOVA model. The aim of
 the primary analysis is to determine whether each treatment is superior to placebo, and if
 both hypotheses hold, the double treatment therapy will be most effective under the additive
 effect assumption of the ANCOVA model. The ANCOVA model compares all subjects who receive
 that treatment with all subjects who do not, irrespective of whether they receive the other
 treatment, after adjusting for the other treatment and age of subject, and is more powerful
 in finding individual treatment effects in the study.

 If interaction between treatments is significant, the ANCOVA model with interaction will
 estimate the treatment effects for each of the four groups. This model is able to test all 6
 contrasts between the four combinations. A hierarchical (gatekeeping) testing strategy to
 maintain a family-wise error rate will be adopted as the following: the first stage will
 compare desipramine or lidocaine individually to placebo with multiplicity-adjusted p-values.
 If a significant difference (one or both null hypotheses rejected) is found for either or
 both individual agents, then the analysis will proceed to the second-stage of hypothesis
 which will compare the effects of the active desipramine/active lidocaine treatment to the
 double placebo. If a significant difference (null hypothesis rejected) is found for combined
 therapy over placebo based on the multiplicity-adjusted p-value, then the final (tertiary)
 stage of comparison will be performed comparing combined therapy to individual therapy. In
 the hierarchical (gatekeeping) testing procedures, inferences in each stage depend on the
 acceptance or rejection of null hypotheses in all previously stages, and each stage serves as
 a gatekeeper for the stages later in the sequence. In our strategy for the model with
 significant interaction effect, if at least one hypothesis has been rejected, then the next
 stage of hypotheses will be tested, and the family-wise error rate is controlled at the .05
 level.

 Secondary analyses will include subset analysis, comparison of the double-active treatment
 group against the others (placebo and the single-treatment groups) on percent change of mean
 "Tampon test" as well as standardized pain measures such as the Brief Pain Inventory and the
 McGill Pain Questionnaire. This is to explore if the active desipramine/active lidocaine
 treatment has more advantages that may not be shown in the ANCOVA model. The secondary
 analysis is to explore supportive evidence to the primary objective of this trial, and no
 confirmatory conclusions are needed. In the secondary analysis, confidence intervals and
 statistical tests are of exploratory nature and no claims are intended.

 Primary and secondary outcome variables will be analyzed according to a modified "intention
 to treat" with "last observation carried forward". The sample analyzed for the primary
 outcome will include the first three or fewer pre-randomization Tampon Test measures and the
 last three or fewer post-randomization Tampon Test measures, up to and including study Week
 12. The subject sample analyzed for drug safety/side effects will include all subjects who
 have taken at least one dose of study drug.
Inclusion Criteria: Candidates must report greater than three continuous months' duration
 of vulvar symptoms of insertional dyspareunia, pain with tampon insertion, or pain to
 touch.

 Physical exam should demonstrate "Friedrich's Criteria" which includes Criterion #1:
 history of severe pain on vestibular touch or attempted vaginal entry for a continuous
 duration of 6 months or greater. Criterion #2: tenderness localized within the vestibule.

 The candidate should not demonstrate any other specific neuropathology Pre-randomization
 laboratory testing should fail to identify atrophic vaginitis, dermatitis such as vulvar
 dystrophy, or pathogens such as fungus, or herpes.

 The candidate should not report use tricyclic-class or topical lidocaine within 30 days of
 the study.

 Candidates will need to be capable of keeping adequate records and demonstrate reliability
 in use of medication.

 If the candidate is premenopausal, adequate contraception will be necessary including oral
 contraceptives, barrier method, progestational contraceptives, vasectomy, tubal ligation,
 and hysterectomy.

 Exclusion Criteria:

 History of cardiac arrhythmia, syncopal episodes, seizures, vulvar cancer, specific
 dermatoses, choreoathetosis or major depression.

 Active infection with herpes simplex, herpes zoster, Bartholin's abscess, Pregnancy, Active
 liver disease or renal disease, Evidence on prior vulvar biopsy or clinical impression of
 specific vulvar dermatoses such as lichen sclerosus, squamous cell hyperplasia, or lichen
 planus Positive culture for fungus (persistence of pain after treatment of particular
 infection and negative culture will not exclude subject from the study) Known
 hypersensitivity to either active agents (desipramine/lidocaine) or cream vehicle
 (Moisturelle cream) Immunocompromised state, History of illicit drug or alcohol abuse
 within the last year Serious or unstable medical or psychiatric conditions, Evidence of
 conduction abnormalities (especially prolonged QT interval) on ECG.

 -